Endocrine Abstracts

Introduction: The 2017 WHO Classification of Pituitary Tumors grades silent corticotroph adenomas (SCAs) as high-risk adenomas due to their aggressive clinical behaviour (high probability of recurrence). Nonetheless, studies comparing recurrence rates of SCA with other non-functioning pituitary adenomas (NFPAs) subtypes have provided conflicting results necessitating review of the evidence this recommendation relies on.Aims: To estimate recurrence rates ...

Context: Evidence suggests that gabapentin, a γ-aminobutyric acid analogue, is effective in the treatment of hot flushes in women with natural or tamoxifen-induced menopause.Objective and design: To investigate the efficacy and tolerability of gabapentin for the treatment of menopausal hot flushes, a systematic review of all pertinent trials and a meta-analysis of those that were randomized placebo-controlled (RCT) were performed.<p class="abste...

Background: Conflicting results regarding adiponectin levels in women with polycystic ovary syndrome (PCOS) have been reported. To evaluate adiponectin levels in PCOS, a systematic review of all studies comparing adiponectin levels in women with PCOS to healthy controls and a meta-analysis of those involving women with similar Body Mass Index (BMI) were performed. Influence of possible effect modifiers, such as insulin resistance (IR) and testosterone, was investigated. Influe...

Background: Although papillary thyroid carcinoma (PTC) is considered to have an excellent prognosis, some more aggressive variants have been identified that show reduced overall survival rates. Besides from the diffuse sclerosing, tall cell, columnar cell, and solid variant, the hobnail variant was newly recognized as one of these aggressive forms, affecting recurrence, metastasis, and overall survival rates.Methods: We performed a systematic review and ...

Background: Primary adrenal insufficiency (PAI) can be of autoimmune origin (Addison’s disease, AD) or due to inborn disorders of steroidogenesis (congenital adrenal hyperplasia, CAH). Prognosis of patients with PAI has improved considerably after glucocorticoid replacement therapy became available. However, even in recent years, an increased risk of death has been described in both AD and CAH patients. Moreover, even with the current state-of-the-art replacement therapy,...

Introduction: Women with non-metastatic breast cancer form a distinct subpopulation in which calcium homeostasis in response to treatment with denosumab has not been extensively investigated.Methods: Female patients with osteoporosis, who were eligible for treatment with denosumab, were prospectively enrolled (2011–2012) and divided into two groups; Group A consisting of patients with either no history or benign diseases non affecting bone metabolis...

Background: Gestational diabetes mellitus (GDM) is associated with adverse perinatal outcomes, and increased risk of post-natal type 2 diabetes and cardiovascular disease. However, whether GDM increases the risk of developing incident Non-alcoholic Fatty Liver Disease (NAFLD) is unclear and has not been well examined in previous studies. This is important considering the significant health burden of NAFLD and the opportunity to interfere in high risk population in order to red...

Tyrosine Kinase Inhibitors (TKIs) have been used in patients with advanced Medullary Thyroid Carcinoma (MTC). However, for some compounds, data on effectiveness and safety are limited. The aim of this systematic review and meta-analysis was to document clinical response and toxicities of TKIs in advanced MTC.Methods: A literature search in MEDLINE, EMBASE and Cochrane until May 2018 was performed for articles or abstracts on TKI use in MTC. Studies were ...

Introduction: Somatostatin analogues (SSAs) are the mainstay of treatment for carcinoid syndrome (CS)-related symptoms. Controversy still exists regarding the extent of the efficacy of this intervention. The purpose of the systematic review and meta-analysis was to evaluate the percentage of patients achieving partial (PR) or complete response (CR) with the use of SSAs (lanreotide, octreotide, pasireotide) in patients with CS. Due to lack of uniformity and established criteria...